Bristol-Myers Squibb Company
ENHANCED PERFORMANCE OF AMORPHOUS SOLID AND SOLUBILIZED FORMULATIONS FOR ACHIEVING THERAPEUTIC PLASMA CONCENTRATIONS

Last updated:

Abstract:

This invention relates to solid amorphous Compound (I) having the formula (I) and to solid amorphous dispersions comprising Compound (I) and one or more polymers or to solution formulations comprising Compound (I) and one or more co-solvents and surfactants. The formulations exhibit enhanced stability and bioavailability. This invention relates to solid amorphous dispersions comprising Compound (I) having the formula (I) and one or more polymers or to solution formulations comprising Compound (I) and one or more co-solvents and surfactants. The formulations exhibit enhanced stability and bioavailability. ##STR00001##

Status:
Application
Type:

Utility

Filling date:

10 Apr 2020

Issue date:

12 May 2022